Vamorolone receives approval by the FDA in the US and positive opinion from CHMP in the EU for use in the treatment of Duchenne muscular dystrophy.

  • The US Food and Drug Administration (FDA) approved vamorolone on October 26, 2023 for the treatment of DMD in children and adults aged two years and olderSanthera’s licensing partner for North America, Catalyst Pharmaceuticals, plans to launch vamorolone in the US in Q1-2024. Catalyst Pharmaceuticals has not announced any plans for Canada. 
  • The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for vamorolone for the treatment of Duchenne muscular dystrophy (DMD) in children and adults aged four years and older. The CHMP is the European Medicines Agency’s committee responsible for human medicines, playing an important role in the authorization of medicines in the European Union.  
  • In its recommendation for approval, the CHMP acknowledges the positive benefit-risk profile of vamorolone in this patient population, including certain safety benefits of vamorolone compared to standard of care corticosteroids in the treatment of DMD. 
  • European Commission (EC) decision on marketing authorization is expected in late 2023. Santhera plans for a first commercial launch in Germany in Q1-2024, subject to approval by the EC. 

Canadian contributions to the clinical development of vamorolone

Several Canadian sites, clinicians, study personnel and many Canadian DMD families have participated in vamorolone’s clinical trials, playing a significant role in testing the drug’s safety and effectiveness, with many study participants still receiving the drug through expanded access to these trials. Canadian patient organization Defeat Duchenne Canada has made significant financial contributions to the development program of vamorolone.

Clinical evidence

The clinical evidence for the efficacy and safety of vamorolone in the regulatory submission was derived from the positive pivotal VISION-DMD study and three open-label studies (including extensions), in which vamorolone was administered at doses between 2 and 6 mg/kg/day for a total treatment period of up to 30 months, as well as an external comparator study (FOR-DMD) and several clinical pharmacology studies. The studies were carried out by Santhera’s partner ReveraGen and 32 academic clinical trial centers in 11 countries, including multiple Canadian sites. 

In the pivotal VISION-DMD study, boys treated with vamorolone on average maintained growth similar to those treated with placebo, whilst those treated with prednisone on average experienced growth stunting. Patients who switched from prednisone to vamorolone after 24-weeks were, on average, able to resume growing in height over the remainder of the study.

On October 27th, 2023 the Journal for Neuromuscular Diseases published the open-access research article Considering the Promise of Vamorolone for Treating Duchenne Muscular Dystrophy”, providing an independent commentary that considers data related to the drug vamorolone (VBP15) as an alternative steroid proposed for treatment of DMD. 

News update reading: Vamorolone receives approval by the FDA in the US and positive opinion from CHMP in the EU for use in the treatment of Duchenne muscular dystrophy.

Read next...

2024 Dr David Green Award winners from MDC

NMD4C Receive Excellence in Service Delivery Award and Network Investigators Honored as part of Muscular Dystrophy Canada’s 2024 Dr David Green Awards

We are excited to share that the NMD4C has been awarded the Excellence in Service Delivery Award, one of the annual Dr David Green Awards presented by Muscular Dystrophy Canada.

NMD4C logo with text reading 'Canadian neuromuscular clinical trials network', MDC and IMHA logos at bottom.

NMD4C Launch Canadian Neuromuscular Clinical Trial Network

We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.

Event organizers and participants from SMA outcome measures training, March 2024 in Quebec.

Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network

This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted. 

MDC award $900 000 towards clinical and translational research projects in 2024.

MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants

Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.

SMA outcome measures training graphic

SMA Outcome Measures Training for Physiotherapists and Occupational Therapists

To support the development and training on validated NMD outcome measures we are pleased to provide opportunities for physiotherapists and occupational therapists to attend training sessions for outcome measures.

Congratulations to the 2024 early career award winners. Dr Mireille Khacho and Dr Jean-Philippe Leduc Gaudet.

Congratulations to the 2024 NMD4C Early Career Awards Recipients

We are excited to announce the recipients of the 2024 NMD4C Early Career Awards! This is the second year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.